BEIJING, Dec. 9, 2024 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that the National Medical Products Administration of the People’s Republic of China has granted approval to the application for the Registration Certificate for Medical Device for the proton therapy equipment (the “Registration Certificate”) made by the Company’s equipment supplier on December 6, 2024.

Stereotaxis (NYSE:STXS) announced today that its Magbot magnetic navigation ablation catheter received regulatory approval in China.

AngioDynamics today announced it received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in patients with intermediate-risk prostate cancer.